Delivery of systemic chemotherapeutic agent to tumors by using focused ultrasound: study in a murine model.

PURPOSE To quantitatively determine the delivery of systemic liposomal doxorubicin to tumors treated with pulsed high-intensity focused ultrasound and to study the mechanism underlying this delivery in a murine model. MATERIALS AND METHODS All animal work was performed in compliance with guidelines and approval of institutional animal care committee. C3H mice received subcutaneous injections in the flank of a cell suspension of SCC7, a murine squamous cell carcinoma cell line; mice (n = 32) in drug delivery study received unilateral injections, whereas mice (n = 10) in mechanistic study received bilateral injections. Tumors were treated when they reached 1 cm(3) in volume. In the drug delivery study, doxorubicin hydrochloride liposomes were injected into the tail vein: Mice received therapy with doxorubicin injections and high-intensity focused ultrasound, doxorubicin injections alone, or neither form of therapy (controls). Tumors were removed, and the doxorubicin content was assayed with fluorescent spectrophotometry. In the mechanistic study, all mice received an injection of 500-kDa dextran-fluorescein isothyocyanate into the tail vein, and half of them were exposed to high-intensity focused ultrasound prior to injection. Contralateral tumors served as controls for each group. Extravasation of dextran-fluorescein isothyocyanate was observed by using in vivo confocal microscopy. RESULTS Mean doxorubicin concentration in tumors treated with pulsed high-intensity focused ultrasound was 9.4 microg . g(-1) +/- 2.1 (standard deviation), and it was significantly higher (124% [9.4 microg . g(-1)/4.2 microg . g(-1)]) than in those that were not treated with high-intensity focused ultrasound (4.2 microg . g(-1) +/- 0.95) (P < .001, unpaired two-tailed Student t test). Extravasation of dextran-fluorescein isothyocyanate was observed in the vasculature of tumors treated with high-intensity focused ultrasound but not in that of untreated tumors. CONCLUSION Pulsed high-intensity focused ultrasound is an effective method of targeting systemic drug delivery to tumor tissue. Potential mechanisms for producing the observed enhancement are discussed.

[1]  D. Tzemach,et al.  Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  E. Kimmel,et al.  Ultrasound-facilitated transport of silver chloride (AgCl) particles in fish skin. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Satoshi Yamada,et al.  Endothelial cell injury in venule and capillary induced by contrast ultrasonography. , 2002, Ultrasound in medicine & biology.

[4]  Douglas L. Miller,et al.  Lithotripter shock waves with cavitation nucleation agents produce tumor growth reduction and gene transfer in vivo. , 2002, Ultrasound in medicine & biology.

[5]  P. Trail,et al.  Monoclonal antibody drug conjugates in the treatment of cancer. , 1999, Current opinion in immunology.

[6]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[7]  J. Lankelma,et al.  Doxorubicin gradients in human breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  M. Dewhirst,et al.  Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. , 2000, Cancer research.

[9]  M. Prausnitz,et al.  Intracellular Drug Delivery Using Low-Frequency Ultrasound: Quantification of Molecular Uptake and Cell Viability , 2001, Pharmaceutical Research.

[10]  Douglas L. Miller,et al.  Tumor growth reduction and DNA transfer by cavitation-enhanced high-intensity focused ultrasound in vivo. , 2003, Ultrasound in medicine & biology.

[11]  Y Wu,et al.  Acoustically active lipospheres containing paclitaxel: a new therapeutic ultrasound contrast agent. , 1998, Investigative radiology.

[12]  N. Rainov,et al.  Ultrasound enhancement of liposome-mediated cell transfection is caused by cavitation effects. , 2000, Ultrasound in medicine & biology.

[13]  W. Pitt,et al.  Investigating the mechanism of acoustically activated uptake of drugs from Pluronic micelles , 2002, BMC Cancer.

[14]  Wen-zhi Chen,et al.  Tumor vessel destruction resulting from high-intensity focused ultrasound in patients with solid malignancies. , 2002, Ultrasound in medicine & biology.

[15]  R K Jain,et al.  Delivery of Molecular Medicine to Solid Tumors , 1996, Science.

[16]  Douglas A Christensen,et al.  Ultrasonic release of doxorubicin from Pluronic P105 micelles stabilized with an interpenetrating network of N,N-diethylacrylamide. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Kullervo Hynynen,et al.  MR imaging-guided focused ultrasound surgery of uterine leiomyomas: a feasibility study. , 2003, Radiology.

[18]  M Intaglietta,et al.  Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Alam,et al.  Radiation-force technique to monitor lesions during ultrasonic therapy. , 2003, Ultrasound in medicine & biology.

[20]  S. Mitragotri,et al.  Ultrasound-mediated transdermal protein delivery , 1995, Science.

[21]  Gregg Trahey,et al.  Acoustic radiation force impulse imaging: in vivo demonstration of clinical feasibility. , 2002, Ultrasound in medicine & biology.

[22]  D. Johnson,et al.  Tumor size: effect on monoclonal antibody uptake in tumor models. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  M. Stuart,et al.  Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. , 1995, Biochimica et biophysica acta.

[24]  M. Dewhirst,et al.  Heat-induced gene expression as a novel targeted cancer gene therapy strategy. , 2000, Cancer research.

[25]  S. S. Hall.  Monoclonal Antibodies at Age 20: Promise at Last? , 1995, Science.

[26]  M. Ranson,et al.  Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. , 2001, Critical reviews in oncology/hematology.

[27]  W. Pitt,et al.  Ultrasonically activated chemotherapeutic drug delivery in a rat model. , 2002, Cancer research.

[28]  D Needham,et al.  A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. , 2000, Cancer research.

[29]  K. Anwer,et al.  Ultrasound enhancement of cationic lipid-mediated gene transfer to primary tumors following systemic administration , 2000, Gene Therapy.

[30]  M. Iannettoni,et al.  Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. , 1998, The Journal of clinical investigation.

[31]  M. Bednarski,et al.  In vivo target-specific delivery of macromolecular agents with MR-guided focused ultrasound. , 1997, Radiology.

[32]  A. Fischman,et al.  Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  N. Rapoport,et al.  Mechanism of the ultrasonic activation of micellar drug delivery. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[34]  Peter Alken,et al.  High intensity focused ultrasound as noninvasive therapy for multilocal renal cell carcinoma: case study and review of the literature. , 2002, The Journal of urology.

[35]  D. Lasič,et al.  Doxorubicin in sterically stabilized liposomes , 1996, Nature.

[36]  Y Lasne,et al.  Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. , 1999, The Journal of urology.

[37]  M. Dewhirst,et al.  Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. , 2001, Cancer research.

[38]  G. Rosner,et al.  Hyperthermic treatment of malignant diseases: current status and a view toward the future. , 1997, Seminars in oncology.

[39]  E. Kimmel,et al.  Ultrasound-induced intercellular space widening in fish epidermis. , 2000, Ultrasound in medicine & biology.

[40]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[41]  W. Oyen,et al.  Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. , 2001, The Journal of pharmacology and experimental therapeutics.

[42]  Narendra T. Sanghvi,et al.  Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report. , 2002, Urology.

[43]  J. Simonin.  On the mechanisms of in vitro and in vivo phonophoresis , 1995 .